Settled
Do investigational compounds improve glycemic control versus placebo?
Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Likely. So far, repeated by independent trials.
NoUnsureYes
- Belief
- 0.78 (range 0.41–0.93)
- Trials for
- 14
- Trials against
- 4
- Inconclusive
- 1
Already under way
- Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes…NCT07400107 · not yet recruiting · started 2026
- Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding StudyNCT07415954 · recruiting · started 2026
- A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in…NCT07505303 · active not recruiting · started 2026
- A Single -Center, Randomized, Double-blind, Placebo-controlled Proof of Exploratory Study Evaluating the Efficacy, Safety, and Tolerability of CS0159 Combined…NCT07570810 · not yet recruiting · started 2026
- BALANCE-DM2: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide…NCT07628985 · not yet recruiting · started 2026
The evidence so far
- Registered trials
- 122
- With posted results
- 40
- Published papers
- 3
Of 264 decided analyses: 164 favor investigational compounds, 88 find no difference, 12 favor the comparator.
Papers
- Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.Trial report · 2025
- Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.Trial report · 2009
- HTD1801 in Combination with Metformin for Type 2 Diabetes.Trial report · 2026
Trials
- A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes MellitusNCT02492763 · 14 posted results
- A Randomized, Placebo Controlled, Repeat Dose, Double Blind (Sponsor Unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes PatientsNCT02202161 · 24 posted results
- A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell FunctionNCT02443155 · 31 posted results
- A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2DNCT03214380 · 9 posted results
- A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin TherapyNCT00792935 · 2 posted results
- Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic PatientsNCT02597101 · 5 posted results
- A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesNCT04867785 · 72 posted results
- A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes MellitusNCT05048719 · 40 posted results